Carcinogenic aspect of xenobiotic molecules belonging to the peroxisome proliferator family

International Journal of Molecular Medicine

Volumn 3, Issue 2, 1999, Pages 163-168

  Cherkaouimalki, Mustapha ^a   Passilly, Patricia ^a   Jannin, Brigitte ^a   Clémencet, Marie Claude ^a   Latruffe, Norbert ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Carcinogenesis; Guinea pig; Peroxisome proliferators; Species specificity

Indexed keywords

CARCINOGEN; PEROXISOME PROLIFERATOR; XENOBIOTIC AGENT;

ANIMAL; ARTICLE; CARCINOGEN TESTING; CELL CULTURE; CELL DIVISION; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; GUINEA PIG; HEPATOMEGALY; HUMAN; ONCOGENE; PHYSIOLOGY; RAT; RODENT;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; GUINEA PIGS; HEPATOMEGALY; HUMANS; ONCOGENES; PEROXISOME PROLIFERATORS; RATS; RODENTIA; TUMOR CELLS, CULTURED; XENOBIOTICS;

EID: 0033068688     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.3.2.163     Document Type: Article

References (24)

1. Latruffe N:Les peroxysomes et la proliferation cellulaire. Médecine/Sciences 8:239-248, 1992.
2. Desvergne B and Wahli W:A key nuclear factor in nutrient/ gene interaction? Inducible Gene Expression. 1:142-176, 1995.
3. Bentley P, Calder I, Elcombe C, et al:Hepatic peroxisome proliferation in rodents and its significance for humans. Fd Chem Toxic 31:857-907, 1993.
4. Reddy JK and Lalwani ND:Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit Rev Toxicol 12:1-58, 1983.
5. Cherkaoui Malki M, Corral-Debrinski M, Lone YC, et al:Differential proto-oncogen mRNA induction from rats treated with peroxisome proliferators. Biochem Biophys Res Commun 173:855-861, 1990.
6. EI-Kebbaj MS, Cherkaoui Malki M and Latruffe N:Properties of peroxisomes from jerboa. Eur J Cell Biol 70:150-156, 1996.
7. Pacot C, Petit M, Rollin M, et al:Difference between guinea pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate. Arch Biochem Biophys 327:181-188, 1996.
8. Brocard C, Es Souni M, Ramirez LC, et al:Stimulation of peroxisomal palmitoyl-CoA oxidase activity by ciprofibrate in hepatic cell lines: comparative studies in Fao, MH1C1 and HepG2 cells. Biol Cell 77:37-41,1993.
9. Passilly P, Jannin B, Hassell SJ, et al:Human HepG2 and rat Fao hepatic-derived cell lines show different responses to ciprofibrate, a peroxisome proliferator: analysis by flow cytometry. Exp Cell Res 223:436-442,1996.
10. Passilly P, Jannin B and Latruffe N:Influence of peroxisome proliferators on phosphoprotein levels in human and rat hepatic derived cell lines. Eur J Biochem 230:316-321, 1995.
11. Latruffe N, Pacot C, Passilly P, et al:Peroxisomes and hepatotoxicity. Comp Haematol Int 5:189-195, 1995.
12. Lazarow PB and de Duve C:A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidaemic drug. Proc Natl Acad Sci USA 73:2043-2046, 1976.
13. Issemann I and Green S:Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650, 1990.
14. Bardot O, Aldridge TC, Latruffe N, et al:PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 192:37-45,1993.
15. Gonzalez FJ:Recent update to the PPARa null mouse. Biochimie 79:139-144,1997.
16. Braissant O, Foufelle F, Scotto C, et al:Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARa, -β and -γ in the adult rat. Endocrinology 137:354-366, 1996.
17. Lee SST, Pineau T, Drago J, et al:Targeted disruption of the a isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012-3023, 1995.
18. Bardot O, Clémencet MC, Cherkaoui Malki M, et al:Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression. Biochem Pharmacol 50:1001-1006, 1995.
19. Miller RT, Glover SE, Stewart WS, et al:Effect on the expression of c-met, c-myc and PPARa in liver and liver tumors from rats chronically exposed to the hepatocarcinogenic peroxisome proliferator Wy-14,643. Carcinogenesis 17:1337-1341, 1996.
20. Ito S, Yoshioka K, Watanabe T, et al:Immunohistochemical demonstration of c-myc oncogene product and glutathione S-transferase (placental form) in rat hepatic preneoplastic lesions induced by diethylnitrosamine and clofibrate. Biomed Res 14:345-351, 1993.
21. Bentley P, Bieri F, Muakkassak-Kelly S, et al:Mechanisms of tumor induction by peroxisome proliferators. Arch Toxicol 12 (Suppl):240-247,1988.
22. Ledwith BJ, Johnson TE, Wagner LK, et al:Growth regulation by peroxisome proliferators: opposing activities in early and late Gl. Cancer Res 56:3257-3264, 1996.
23. O'Brien ML, Rangwala SM, Henry W, et al:Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis. Carcinogenesis 17:185-190, 1996.
24. Hsieh LL, Shinozuka H and Weinstein IB:Changes in expression of cellular oncogenes and endogenous retrovirus-like sequences during hepatocarcinogenesis induced by a peroxisome proliferator. Br J Cancer 64:815-820,1991.